Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q4 CY2025 results exceeding the market’s revenue ...
Live and archived webcasts of the sessions may be viewed on the Investor Relations section of the Company’s website at ir.neogenomics.com. NeoGenomics, Inc. is a premier cancer diagnostics company ...
Interactive Use of Cox Model–Predicted Survival Curves: An Application Using ACS10 Score and Age to Personalize Treatment of Pediatric AML Patients who received both T-DXd and SG for treatment of MBC ...
NeoGenomics announced the launch of RaDaR® ST, its circulating tumor DNA assay for detecting molecular residual disease.
Detailed price information for Laboratory Corp of America Holdings (LH-N) from The Globe and Mail including charting and ...
NeoGenomics (NEO) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.04 per share a year ago. These figures ...
FORT MYERS, Fla. (AP) — FORT MYERS, Fla. (AP) — NeoGenomics Inc. (NEO) on Tuesday reported a loss of $9.9 million in its fourth quarter. The Fort Myers, Florida-based company said it had a loss of 8 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results